Quell Therapeutics expands Series A financing to $84m
Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd, who have committed an additional $34.7 million and UCL Technology Fund who have committed an additional $1 million; bringing the total Series A financing to circa $84 million.
Quell is funded to progress its program in liver transplantation to clinical proof of concept, whilst expanding its portfolio into autoimmune and neuroinflammatory diseases. Additionally, the funding will allow the Company to further develop scalable manufacturing processes and expand its senior leadership team.
Tanel Ozdemir, Investor at UCL Technology Fund:
“We are delighted to continue supporting Quell in their world-leading efforts with Treg therapies. The team have made great progress on several challenging fronts over the last year, and we firmly believe that they are at the cutting-edge of this exhilarating field. Quell continues to be a great example of what can be achieved in a collaborative and interdisciplinary approach between several leading institutions.”
Learn more here